Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immune Tolerance Level Predicts Leukemia Outcome

By LabMedica International staff writers
Posted on 04 Dec 2017
Measurement of messenger RNA (mRNA) encoding an enzyme that augments tumor-induced immune tolerance was shown to be predicative of the outcome for patients with leukemia.

Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in the kynurenine pathway that augments tumor-induced immune tolerance. More...
Previous studies in childhood acute myeloid leukemia (AML) have shown a negative correlation of IDO-1 mRNA expression with outcomes. In other words, increased IDO expression in bone marrow biopsies correlated with lower overall survival rates and early mortality.

Investigators at the Medical College of Georgia at Augusta University, USA) set out to develop a practical and objective immunohistochemical technique to quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate its use in routine clinical practice.

In establishing the procedure, the investigators extracted IDO-1 mRNA from diagnostic bone marrow specimens from 29 AML patients. IDO-1 protein expression was assessed in 40 cases via immunohistochemistry and quantified by a novel "composite IDO-1 score."

Results revealed that a higher composite IDO-1 score could accurately predict poor outcomes. Further, patients who failed induction therapy (chemotherapy for AML) had higher composite IDO-1 scores. Therefore, the "composite IDO-1 score" was demonstrated to be a prognostic tool that could help identify a certain subset of AML patients with "early mortality." This unique subset of patients could potentially benefit from specific IDO-1 inhibitor therapy, currently in clinical trials.

"We want to help people who are not responding to treatment and are dying very soon after their diagnosis," said senior author Dr. Ravindra Kolhe, associate professor of pathology at the Medical College of Georgia at Augusta University. "Most of the time, we do not know why patients are not responding to chemotherapy. Right now we know it is high in patients who die at six months and we show that it is an independent indicator if you adjust for other known variables."

The study was published in the October 16, 2017, online edition of the journal Scientific Reports.

Related Links:
Medical College of Georgia at Augusta University


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.